Actively Recruiting
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-02-10
100
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the effectiveness of a new model to evaluate comprehensive treatment for hepatocellular carcinoma (HCC), a common and deadly liver cancer. The model uses factors like PD-L1 expression, tertiary lymphoid structures (TLS), and vascular endothelial growth factor (VEGF) levels to predict treatment outcomes. This study aims to help classify patients accurately and guide treatment decisions by comparing comprehensive therapy involving immunotherapy and targeted therapy to standard treatment plans. Participants will be randomly assigned to one of two groups: one receiving immunotherapy combined with targeted therapy, and the other receiving the standard treatment plan. The study will assess the efficacy of these approaches using the constructed predictive model. This randomized controlled trial is based on prior retrospective analysis and intends to validate the model's accuracy and practical use. During the study, patients will be followed for about one year after treatment to evaluate treatment effectiveness and the predictive accuracy of the model. Researchers will monitor long-term outcomes and use measures like sensitivity, specificity, and the area under the receiver operating characteristic (ROC) curve to assess the model's performance. This follow-up will help determine how well the model predicts patient responses to comprehensive treatment for liver cancer.
CONDITIONS
Brief Title
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with advanced hepatocellular carcinoma
- Aged between 18 and 75 years
You will not qualify if you...
- Severe diabetes, heart failure, liver or kidney failure
- History of schizophrenia
- History of other malignant tumors or metastatic liver tumors discovered after surgery
- Received anti-tumor drugs for other diseases
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration of treatment as per assigned treatment plan
Participants receive either immunotherapy combined with targeted therapy or a standard treatment plan for advanced hepatocellular carcinoma.
Visit schedule depends on treatment assignment
Duration - Approximately 1 year
Participants are followed long-term after treatment to evaluate treatment efficacy and the predictive accuracy of the treatment efficacy model.
Regular follow-up visits during the 1-year period
Trial Site Locations
Total: 1 location
1
2ndAffiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here